These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 26282344)

  • 1. Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials.
    Thomopoulos C; Skalis G; Michalopoulou H; Tsioufis C; Makris T
    Clin Cardiol; 2015 Dec; 38(12):763-9. PubMed ID: 26282344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
    Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial.
    Murphy SA; Cannon CP; Blazing MA; Giugliano RP; White JA; Lokhnygina Y; Reist C; Im K; Bohula EA; Isaza D; Lopez-Sendon J; Dellborg M; Kher U; Tershakovec AM; Braunwald E
    J Am Coll Cardiol; 2016 Feb; 67(4):353-361. PubMed ID: 26821621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
    Lancellotti P; Pierard LA; Scheen AJ
    Rev Med Liege; 2015 Sep; 70(9):450-5. PubMed ID: 26638446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials.
    Battaggia A; Donzelli A; Font M; Molteni D; Galvano A
    PLoS One; 2015; 10(4):e0124587. PubMed ID: 25915909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
    Baigent C; Landray MJ; Reith C; Emberson J; Wheeler DC; Tomson C; Wanner C; Krane V; Cass A; Craig J; Neal B; Jiang L; Hooi LS; Levin A; Agodoa L; Gaziano M; Kasiske B; Walker R; Massy ZA; Feldt-Rasmussen B; Krairittichai U; Ophascharoensuk V; Fellström B; Holdaas H; Tesar V; Wiecek A; Grobbee D; de Zeeuw D; Grönhagen-Riska C; Dasgupta T; Lewis D; Herrington W; Mafham M; Majoni W; Wallendszus K; Grimm R; Pedersen T; Tobert J; Armitage J; Baxter A; Bray C; Chen Y; Chen Z; Hill M; Knott C; Parish S; Simpson D; Sleight P; Young A; Collins R;
    Lancet; 2011 Jun; 377(9784):2181-92. PubMed ID: 21663949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis.
    Navarese EP; Robinson JG; Kowalewski M; Kolodziejczak M; Andreotti F; Bliden K; Tantry U; Kubica J; Raggi P; Gurbel PA
    JAMA; 2018 Apr; 319(15):1566-1579. PubMed ID: 29677301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT.
    Oyama K; Giugliano RP; Blazing MA; Park JG; Tershakovec AM; Sabatine MS; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2021 Oct; 78(15):1499-1507. PubMed ID: 34620406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complementary therapy to target LDL cholesterol: the role of the ezetimibe/simvastatin combination.
    Neal RC; Jones PH
    Vasc Health Risk Manag; 2006; 2(1):31-8. PubMed ID: 17319467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia.
    Patel JV; Hughes EA
    Int J Clin Pract; 2006 Aug; 60(8):914-21. PubMed ID: 16893434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study.
    Ballantyne CM; Abate N; Yuan Z; King TR; Palmisano J
    Am Heart J; 2005 Mar; 149(3):464-73. PubMed ID: 15864235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.
    Blazing MA; Giugliano RP; Cannon CP; Musliner TA; Tershakovec AM; White JA; Reist C; McCagg A; Braunwald E; Califf RM
    Am Heart J; 2014 Aug; 168(2):205-12.e1. PubMed ID: 25066560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
    Bays HE; Ose L; Fraser N; Tribble DL; Quinto K; Reyes R; Johnson-Levonas AO; Sapre A; Donahue SR;
    Clin Ther; 2004 Nov; 26(11):1758-73. PubMed ID: 15639688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy.
    Lorenzi M; Ambegaonkar B; Baxter CA; Jansen J; Zoratti MJ; Davies G
    Clin Res Cardiol; 2019 May; 108(5):487-509. PubMed ID: 30302558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial.
    Goldberg AC; Sapre A; Liu J; Capece R; Mitchel YB;
    Mayo Clin Proc; 2004 May; 79(5):620-9. PubMed ID: 15132403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
    Cannon CP; Blazing MA; Giugliano RP; McCagg A; White JA; Theroux P; Darius H; Lewis BS; Ophuis TO; Jukema JW; De Ferrari GM; Ruzyllo W; De Lucca P; Im K; Bohula EA; Reist C; Wiviott SD; Tershakovec AM; Musliner TA; Braunwald E; Califf RM;
    N Engl J Med; 2015 Jun; 372(25):2387-97. PubMed ID: 26039521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS; Mikhailidis DP
    Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
    Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White JA; Tershakovec AM; Blazing MA; Braunwald E
    Circulation; 2015 Sep; 132(13):1224-33. PubMed ID: 26330412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study.
    Goldberg RB; Guyton JR; Mazzone T; Weinstock RS; Polis A; Edwards P; Tomassini JE; Tershakovec AM
    Mayo Clin Proc; 2006 Dec; 81(12):1579-88. PubMed ID: 17165637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia.
    Yoon HS; Kim SH; Kim JK; Ko SH; Ko JE; Park SJ; Park MG; Lee JH; Hyon MS
    Ann Pharmacother; 2011 Jul; 45(7-8):841-9. PubMed ID: 21693699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.